Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24535149 | 0.90 | MEN1 (0.40) | MEN1KMT2AGPR119CYBBNOX5 | |
| SCHEMBL31057453 | 0.88 | GPR119 (0.37) | MEN1KMT2AGPR119CYBBNOX5 | |
| SCHEMBL25337280 | 0.84 | NR1H2 (0.42) | MEN1KMT2ACYBBNOX5NOX4 | |
| SCHEMBL25335687 | 0.84 | MEN1 (0.43) | MEN1KMT2ACYBBNOX5NOX4 | |
| SCHEMBL26686738 | 0.84 | MEN1 (0.43) | MEN1KMT2AGPR119CYBBNOX5 | |
| SCHEMBL30793124 | 0.81 | MEN1 (0.40) | MEN1KMT2ACYBBNOX5NOX4 | |
| SCHEMBL26686561 | 0.81 | HPGD (0.41) | MEN1KMT2ACYBBNOX5NOX4 | |
| SCHEMBL30793952 | 0.80 | KMT2A (0.46) | MEN1KMT2ACYBBNOX5NOX4 | |
| SCHEMBL26687047 | 0.80 | ADORA1 (0.42) | MEN1KMT2AGPR119CYBBNOX5 | |
| SCHEMBL26890664 | 0.79 | MEN1 (0.42) | MEN1KMT2ACYBBNOX5NOX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665735-A1 | KRAS INHIBITORS | Erasca, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025245105-A1 | KRAS INHIBITORS | ERASCA, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250243222-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025106905-A1 | COMBINATION THERAPIES WITH A KRAS MODULATOR AND AN IMMUNOMODULATOR INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4532494-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12145947-B2 | Pyrimidine based modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024173842-A1 | KRAS INHIBITORS | ERASCA, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145947-B2 | Pyrimidine based modulators and uses thereof | KRAS, NRAS, DPYD | MEN1 2585/4885KMT2A 3004/4885GPR119 161/4885 |
| US-20250243222-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | KRAS, NRAS, DPYD | MEN1 2585/4885KMT2A 3004/4885GPR119 161/4885 |
| US-20240199650-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | KRAS, NRAS, DPYD | MEN1 2585/4885KMT2A 3004/4885GPR119 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.